Compare Effectiveness of Eplerenone vs Atenolol in Reversing the Remodelling Resistance Arteries in Subjects With HT

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the impact of antihypertensive therapy with the selective mineralocorticoid receptor blocker, eplerenone, on small resistance artery remodeling, compared to the effect of equivalent blood pressure control achieved with a b-blocker, atenolol.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Atenolol; Eplerenone; Spironolactone

Criteria

Inclusion Criteria:

• Pt with essential hypertension who have never been treated or untreated within the previous 6 months

Exclusion Criteria:

• History of Malignant Hypertension

• Sitting diastolic blood pressure > 115mmHg or sitting Systolic blood pressure > 200mmHg